ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Current state of CAR-T therapy for T-cell malignancies

Luo, Liangkui; Zhou, Xuan; Zhou, Lijuan; Liang, Zhao; Yang, Jilong; Tu, Sanfang*; Li, Yuhua*南方医科大学
Therapeutic Advances in Hematology2022-12DOI: 10.1177/20406207221143025
6被引5阅读
引用收藏
分享

摘要

Chimeric antigen receptor T-cell (CAR-T) therapy has been approved for relapsed/refractory B-cell lymphomas and greatly improves disease outcomes. The impressive success has inspired the application of this approach to other types of tumors. The relapsed/refractory T-cell malignancies are characteristic of high heterogeneity and poor prognoses. The efficacy of current treatments for this group of diseases is limited. CAR-T therapy is a promising solution to ameliorate the current therapeutic situation. One of the major challenges is that normal T-cells typically share mutual antigens with malignant cells, which causes fratricide and serious T-cell aplasia. Moreover, T-cells collected for CAR transduction could be contaminated by malignant T-cells. The selection of suitable target antigens is of vital importance to mitigate fratricide and T-cell aplasia. Using nanobody-derived or naturally selected CAR-T is the latest method to overcome fratricide. Allogeneic CAR-T products and CAR-NK-cells are expected to avoid tumor contamination. Herein, we review the advances in promising target antigens, the current results of CAR-T therapy clinical trials in T-cell malignancies, the obstacles of CAR-T therapy in T-cell malignancies, and the solutions to these issues.

学科与关键词

关键词
chimeric antigen receptorfratricideimmunotherapyT-cell aplasiaT-cell leukemiaT-cell lymphoma
相关
加载中…
  • CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
    Zhang, Xiaomin; Zhu, Lingling; Zhang, Hui; Chen, Shanshan; Xiao, Yang*Frontiers in Immunology, 2022, 13: 927153.被引 47
  • CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities
    Ren, Anqi; Tong, Xiqin; Xu, Na; Zhang, Tongcun; Zhou, Fuling*; Zhu, Haichuan*Vaccines, 2023, 11(1): 165.被引 7
  • Tumor buster-where will the CAR-T cell therapy 'missile' go?
    Qu, Chunrun; Zhang, Hao; Cao, Hui; Tang, Lanhua; Mo, Haoyang; Liu, Fangkun; Zhang, Liyang; Yi, Zhenjie; Long, Lifu; Yan, Luzhe; Wang, Zeyu; Zhang, Nan; Luo, Peng; Zhang, Jian; Liu, Zaoqu; Ye, Weijie; Liu, Zhixiong*; Cheng, Quan*Molecular Cancer, 2022, 21(1): 201.被引 24
查看全部 →

发表信息

论文状态
公开发表
期刊
Therapeutic Advances in Hematology
发表日期
2022-12
卷期
第 13 卷
页码
20406207221143025
DOI
10.1177/20406207221143025
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [U2001224]; Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR110105014]

作者

  • L

    Luo, Liangkui (第一作者)

    southern med univ

  • Z

    Zhou, Xuan

    southern med univ

查看全部 7 位作者收起作者
  • Z

    Zhou, Lijuan

    southern med univ

  • L

    Liang, Zhao

    southern med univ

  • Y

    Yang, Jilong

    southern med univ

  • T

    Tu, Sanfang (通讯)

    southern med univ

  • L

    Li, Yuhua (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417